Dr. Sandra Horning joined Revolution Medicines’ (RVMD) board of directors at the closing of the EQRx (EQRX) acquisition as a Class II director, with a term expiring at the company’s 2025 annual meeting of stockholders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RVMD:
- Revolution Medicines Completes Acquisition of EQRx
- Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
- Revolution Medicines, EQRx stockholders approve EQRx acquisition
- Revolution Medicines reports Q3 EPS (99c), consensus ($1.01)
- Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
